ex vivo approach
Recently Published Documents


TOTAL DOCUMENTS

62
(FIVE YEARS 6)

H-INDEX

13
(FIVE YEARS 0)

Author(s):  
Sanchaita Misra ◽  
Aniruddha Bagchi ◽  
Avik Sarkar ◽  
Sougata Niyogi ◽  
Dipanjan Bhattacharjee ◽  
...  


2021 ◽  
Vol 72 ◽  
pp. 105099
Author(s):  
Lorena Polloni ◽  
Fernanda Van Petten Vasconcelos Azevedo ◽  
Samuel Cota Teixeira ◽  
Eloá Moura ◽  
Tassia Rafaela Costa ◽  
...  


Author(s):  
Sébastien Baekelandt ◽  
Valérie Cornet ◽  
Syaghalirwa.N.M. Mandiki ◽  
Lambert Jérôme ◽  
Dubois Mickaël ◽  
...  


2021 ◽  
Vol 232 ◽  
pp. 105767
Author(s):  
Giovana Souza Branco ◽  
Renata Guimarães Moreira ◽  
Maria Inês Borella ◽  
Marília de Paiva Camargo ◽  
Marcela Muñoz-Peñuela ◽  
...  


Cells ◽  
2021 ◽  
Vol 10 (1) ◽  
pp. 132
Author(s):  
Johanna Simon ◽  
Gabor Kuhn ◽  
Michael Fichter ◽  
Stephan Gehring ◽  
Katharina Landfester ◽  
...  

Understanding the behavior of nanoparticles upon contact with a physiological environment is of urgent need in order to improve their properties for a successful therapeutic application. Most commonly, the interaction of nanoparticles with plasma proteins are studied under in vitro conditions. However, this has been shown to not reflect the complex situation after in vivo administration. Therefore, here we focused on the investigation of magnetic nanoparticles with blood proteins under in vivo conditions. Importantly, we observed a radically different proteome in vivo in comparison to the in vitro situation underlining the significance of in vivo protein corona studies. Next to this, we found that the in vivo corona profile does not significantly change over time. To mimic the in vivo situation, we established an approach, which we termed “ex vivo” as it uses whole blood freshly prepared from an animal. Overall, we present a comprehensive analysis focusing on the interaction between nanoparticles and blood proteins under in vivo conditions and how to mimic this situation with our ex vivo approach. This knowledge is needed to characterize the true biological identity of nanoparticles.



Molecules ◽  
2020 ◽  
Vol 25 (24) ◽  
pp. 5877
Author(s):  
Panudda Dechwongya ◽  
Songpol Limpisood ◽  
Nawong Boonnak ◽  
Supachoke Mangmool ◽  
Mariko Takeda-Morishita ◽  
...  

The capacity of α-mangostin (α-MG) and β-mangostin (β-MG) from mangosteen pericarp on P-glycoprotein (Pgp) in silico, in vitro, and ex vivo was investigated in this study. Screening with the ADMET Predictor™ program predicted the two compounds to be both a Pgp inhibitor and Pgp substrate. The compounds tended to interact with Pgp and inhibit Pgp ATPase activity. Additionally, bidirectional transport on Caco-2 cell monolayers demonstrated a significantly lower efflux ratio than that of the control (α-(44.68) and β-(46.08) MG versus the control (66.26); p < 0.05) indicating an inhibitory effect on Pgp activity. Test compounds additionally revealed a downregulation of MDR1 mRNA expression. Moreover, an ex vivo absorptive transport in everted mouse ileum confirmed the previous results that α-MG had a Pgp affinity inhibitor, leading to an increase in absorption of the Pgp substrate in the serosal side. In conclusion, α- and β-MG have the capability to inhibit Pgp and they also alter Pgp expression, which makes them possible candidates for reducing multidrug resistance. Additionally, they influence the bioavailability and transport of Pgp substrate drugs.



2020 ◽  
Vol 164 ◽  
pp. 103652
Author(s):  
Julia Torres-Velarde ◽  
Raúl Llera-Herrera ◽  
Teresa García-Gasca ◽  
Alejandra García-Gasca




2020 ◽  
Vol 11 ◽  
Author(s):  
Michelle Thönnes ◽  
Marlen Vogt ◽  
Katja Steinborn ◽  
Krist N. Hausken ◽  
Berta Levavi-Sivan ◽  
...  


Sign in / Sign up

Export Citation Format

Share Document